Paul has over 40 years’ experience in the pharmaceutical and life science arena. A graduate chemist, he initially worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups. He acted as interim CEO to NanoMab Technology Ltd as well as serving as Managing Partner and board member of the global Executive Search Group, Horton International. Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering (1999). In 1997 he received an MBE for services to biotechnology. Paul joined the OBN Board in March 2021.
Alina Dulija Joins Us
The SCi Partners team has been further augmented by the arrival of Alina Dulija as Senior Researcher. Alina is a multi-lingual life science researcher who